Literature DB >> 18568728

Glioblastoma multiforme of the lateral ventricle: report of nine cases.

H I Secer1, C Dinc, I Anik, B Duz, E Gonul.   

Abstract

Glioblastoma multiforme is the most common lethal primary central nervous system (CNS) tumour in adults and they are rarely seen as primary intraventricular tumours. We present nine cases with lateral ventricle glioblastoma multiforme treated in our department. Seven of the nine tumours were located at the body of the lateral ventricle, whereas the other tumours were arising from septum pellicidum. Five patients were operated through an anterior transcallosal approach and four patients were operated through frontal transcortical approach. Total tumour excision was achieved only in one patient. Median survival time was 18.8 months. Three patients were alive at the end of study, and received radiotherapy and chemotherapy. Our goal was the decompressive surgery for these tumours without harming eloquent structures. In our opinion, patient's life quality is critically important in the postoperative period for these mortal tumours with rapid progression.

Entities:  

Mesh:

Year:  2008        PMID: 18568728     DOI: 10.1080/02688690701867254

Source DB:  PubMed          Journal:  Br J Neurosurg        ISSN: 0268-8697            Impact factor:   1.596


  3 in total

1.  Optimization of Glioblastoma Mouse Orthotopic Xenograft Models for Translational Research.

Authors:  Susan M Irtenkauf; Susan Sobiechowski; Laura A Hasselbach; Kevin K Nelson; Andrea D Transou; Enoch T Carlton; Tom Mikkelsen; Ana C deCarvalho
Journal:  Comp Med       Date:  2017-08-01       Impact factor: 0.982

2.  Intraventricular glioblastoma multiforme mimicking meningioma and review of the literature.

Authors:  Ashis Patnaik; Sudhansu S Mishra; Satya B Senapati
Journal:  Asian J Neurosurg       Date:  2017 Jan-Mar

3.  Trigone ventricular glioblastoma multiforme with trapped temporal horn: A case report.

Authors:  Lei Liu; Shaozhen Wang; Xuetao Dong; Yaodong Liu; Liudong Wei; Linghong Kong; Qingjun Zhang; Kun Zhang
Journal:  Front Oncol       Date:  2022-09-13       Impact factor: 5.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.